The combination of the AstraZeneca and Sputnik Light vaccines against Covid-19 demonstrated “an acceptable safety profile”. The diagnosis was published in a study carried out by the laboratories that produce these drugs, in which it was ensured that the result “could provide a safe, effective and long-term protection” against new variants of the virus.
Research done by Russian Direct Investment Fund (RDIF), the Gamaleya Center, AstraZeneca and R-Pharm is the first to evaluate the combined use of components from different adenovirus vaccines to prevent coronavirus infection.
What the study showed
The combination of vaccines demonstrated “an acceptable security profile”which is consistent with the results of previous studies of the AstraZeneca, Sputnik V, and Sputnik Light (the first component of the Sputnik V vaccine) vaccines.
That is to say, the results “support the mix-and-match approach to revaccination”said the executive director of Rdif, Kirill Dmitriev, through a statement.
“With concern in the face of new dangerous variants emerging, this approach could provide safe protectioneffective and long-term,” he remarked.
The World Health Organization estimates that the interchangeability of different vaccines will allow a greater flexibility in vaccination programsand will increase the efficacy and affordability of vaccines.
How and where was the study
According to the provisional results, they are the product of phase II clinical trials were made in 100 volunteers in Russia and another 100 in Azerbaijan.
In the study presented Monday, volunteers were followed for 57 days after the first dose and follow-up results
found “a good safety profile of the combination”while no serious adverse events were recorded.
For his part, the executive director of the R-Pharm group, Vasily Ignatiev, indicated that “The current safety data add to the data on the previously announced high immunogenicity profile of the vaccine combination”.
–
